Receive instant alerts for news on your actions. Claim your 1-week free trial for Street Insider Premium here.
Highly accomplished executive with a proven track record of leading healthcare companies
Q Saeed becomes consultant for the company
MOUNT VERNON, NY / ACCESSWIRE / December 9, 2021 / Applied UV, Inc. (NASDAQ: AUVI) (“Applied UV” or the “Company”), an industry leader in air and surface pathogen removal technology, announced today that its Board of Directors has appointed James Alecxih as a member of the Board of Directors of the Company, effective December 8, 2021. Mr. Alecxih’s appointment follows the resignation of Keyoumars (“Q”) Saeed, who served as Chief Executive Officer since June 30, 2020, prior to the Company’s initial public offering (“IPO”) on August 31, 2020. Mr. Saeed will act as a consultant to the Company for a period of up to up to six months, focusing primarily on evaluating potential synergistic acquisitions.
During his tenure at Applied UV, Mr. Saeed was instrumental in leading the company’s successful IPO on the Nasdaq, strengthening the management team, formulating a business development strategy and by creating a global infrastructure of resellers and distributors. Mr. Saeed also led the formation of a digital marketing strategy to launch a DTC consumer channel. While at Applied UV, Mr. Saeed successfully executed a secondary equity offering and a senior offering to support the company’s growth strategy and fund three accretive acquisitions in the disinfection space.
Max Munn, Founder and Chairman of Sterilumen, said: “On behalf of the Applied UV Board of Directors, I would like to thank Q Saeed for his outstanding service as CEO. Under his leadership, the company made significant progress on a series of important initiatives, including the execution of a capital formation strategy to enable the significant acquisition activity and associated integration, advancing our operational goals and prepare the company for long-term success and value creation. We appreciate Q’s contributions and wish him the best of luck. “
Commenting on the appointment of James Alecxih as CEO, Joel Kanter, Non-Executive Chairman of the Board, said: “The Board of Directors of Applied UV is delighted to appoint Jim as CEO. After extensive research and careful consideration, our Board of Directors has unanimously concluded that Jim has the right mix of skills, experience and talent to lead Applied UV to reach his full potential. Jim has extensive experience in the global sales and distribution of medical devices and technologies. In addition, he has a solid track record of managing global sales for healthcare companies and partnering with healthcare professionals, which will be essential for Applied UV as we continue to execute on our strategy. growth, accelerate innovation and advance our pathogen elimination product portfolio. “
“I would like to thank the Board of Directors for placing their trust in me,” said James Alecxih. “It is truly an honor to be the next CEO of Applied UV. I firmly believe Applied UV is well positioned to serve our customers by providing complete solutions on a global scale. I look forward to working with dedicated employees to drive growth in this attractive market and building on our recognized market leadership position in the pathogen removal and air purification industry. “
Prior to joining Applied UV, Mr. Alecxih was President and CEO of Vivebio Scientific, developer of a proprietary vertical flow dried plasma separation device that enables high volume viral load testing, lipid panels and mass spectrometry. Prior to Vivebio, Mr. Alecxih served as Commercial Director at ViewRay, where he managed global sales, marketing and training for a start-up radiation oncology company. Mr. Alecxih also spent 14 years at Intuitive Surgical, a global leader in minimally invasive care technology and the pioneer of the da Vinci® Robot-Assisted Surgery System, where he last served as Senior Vice President of sales for North America, South America, Australia and New Zealand. At Intuitive Surgical, Jim has been instrumental in driving sales from $ 9 million per year to over $ 1.8 billion per year and coordinated the overall marketing strategy through four product launches and nationwide expansion. and international.
Earlier in his career, Mr. Alecxih held various sales management positions at Johnson & Johnson’s Ethicon Endo-Surgery. He holds a Bachelor of Arts in Business from Le Tourneau University in Longview, Texas.
About applied UVs
Applied UV is focused on the development and acquisition of infection control technologies in the healthcare, hospitality, commerce and municipal markets. The Company has two wholly owned subsidiaries – SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s Connected Platform for Data-Driven Disinfection “applies the power of ultraviolet light (UVC) to destroy pathogens safely, completely and automatically, addressing the challenge of nosocomial infections (” HAIs “) . In revenue such as hospitals, hotels, commercial facilities and other public spaces, the company’s “Lumicide” platform uses UVC LEDs in several patented designs for infection control in and around high-pressure areas. traffic, including sinks and toilets, killing bacteria, viruses and other pathogens residing on hard surfaces near appliances. The company’s patented drain disinfection device, Lumicide Drain, is the only product on the market that tackles this critical, pathogen-intensive location. SteriLumen’s Airocide® products for air purification, developed for NASA and FDA, approved as Class II medical devices, use proprietary photocatalytic bioconversion technology that draws air into a reaction chamber that converts molds, microorganisms, dangerous pathogens, destructive VOCs and biological gases. into harmless water vapor without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, chain grocery stores, winemaking facilities, commercial real estate, schools, dental offices and homes.
For more information about Applied UV, Inc. and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/; https://sterilumen.com/; and https://munnworks.com/.
The information contained in this document may contain “forward-looking statements”. Forward-looking statements reflect the current view of future events. When used in this press release, the words “anticipate”, “believe”, “estimate”, “expect”, “the future”, “intend”, “plan” or the negative of such terms and similar expressions, as they relate to us or our management, identify forward-looking statements. These statements include, but are not limited to, statements in this press release regarding the opinion of the management of Applied UV with respect to its business strategy, future results of operations and prospects for liquidity and capital resources. . Forward-looking statements are based on the Company’s current expectations and assumptions regarding its business, economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The actual results of the Company may differ materially from those contemplated by forward-looking statements. They do not constitute statements of historical fact or guarantees of future performance. We therefore advise you not to rely on any of these forward-looking statements. Factors or events that could cause the actual results of the Company to differ may occur from time to time and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, activity levels, performance or achievements. Except as required by applicable law, including United States securities laws, the Company does not intend to update any forward-looking statements to conform them to actual results.
Applied UV Investor Relations
THE SOURCE: Applied UV, Inc.
See the source version on accesswire.com: